Concomitant increases in serum growth hormone and hypothalamic @entity1943 in @entity35 after injection of XXXX , @entity11086 , or @entity2932 .

@entity4485 @entity1246 @entity4774 @entity2933 @entity2932 @entity11086 @entity35 @entity1943
@entity1246 ( @entity1246 ; 50 or 500 microgram/10 microliter) was injected into the right lateral ventricle of @entity4774 - or @entity4485 -anesthetized male @entity35 . The animals were decapitated 15 min after injection. Serum GH and hypothalamic @entity1943 (SRIF) concentration were measured by specific RIAs. Intraventricular @entity1246 caused a dose-related increase in GH and SRIF. In another study, @entity11086 (5 or 20 mg) was injected ip into @entity4774 -anesthetized @entity35 . @entity11086 at 20 mg produced a significant increase in both serum GH and hypothalamic SRIF. Furthermore, 12.5 mg @entity2932 ( @entity2933 ) injected ip into @entity4774 - or @entity4485 -anesthetized @entity35 elicited a significant increase in both serum GH and hypothalamic SRIF. Pretreatment with 20 mg L-dopa produced decreases in the @entity2933 -induced serum GH increase and in hypothalamic SRIF in @entity4485 -anesthetized @entity35 . These results show that @entity1246 and @entity2933 stimulated GH secretion, which was accompanied by increased hypothalamic SRIF. Thus, the GH release induced by @entity1246 or @entity2933 may be partly involved in inhibiting the release of hypothalamic SRIF. As the @entity2933 -induced GH release was inhibited by L-dopa, the stimulatory effect of @entity2933 on GH secretion might be mediated by inhibition of the dopaminergic mechanism.
